Skip to main content

Table 2 Baseline laboratory data of stroke patients in the two groups

From: Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke

 

With pre-existing statin use (n= 43)

Without pre-existing statin use (n= 129)

Pvalue

White blood cells (X103/ml)

7.5 ± 0.4

7.5 ± 0.3

0.86

Red blood cells (X106/ml)

4.6 ± 0.1

4.7 ± 0.1

0.71

Platelet counts (X104/ml)

20.2 ± 1.1

21.9 ± 0.7

0.43

Total cholesterol (mg/dl)†

148.3 ± 4.3

218.8 ± 6.5

< 0.0001

LDL-cholesterol (mg/dl)†

83.0 ± 3.7

142.9 ± 5.1

< 0.0001

HDL-cholesterol (mg/dl)†

40.3 ± 1.6

42.8 ± 1.5

0.27

Triglyceride (mg/dl)

125.3 ± 8.3

176.3 ± 14.7

0.04

HbA1c (%)

7.3 ± 0.3

7.1 ± 0.3

0.43

APTT (second)

28.0 ± 0.5

27.9 ± 0.4

0.91

PT (second)

10.2 ± 0.1

10.1 ± 0.1

0.37

Systolic BP (mmHg)

138.7 ± 2.4

146.6 ± 2.4

0.13

Diastolic BP (mmHg)

80.1 ± 1.3

85.2 ± 1.6

0.10

CD62P (%)†

2.2 ± 0.6

3.9 ± 0.5

0.01

CD63 (%)†

1.2 ± 0.2

1.8 ± 0.5

0.03

  1. APTT, activated partial thromboplastin time; BP, blood pressure; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; PT, prothrombin time.
  2. † The data was expressed as primitive data, and the P value was obtained from those primitive data that were logarithmically transformed to improved normality and compared by independent -t test.
Back to article page

Critical Care

ISSN: 1364-8535